XML 18 R12.htm IDEA: XBRL DOCUMENT
v3.24.3

Note 3 - Balance Sheet Details | 9 Months Ended
--- | ---
Sep. 30, 2024
Disclosure Text Block [Abstract] |
Balance Sheet Details | 3. Balance Sheet Details Prepaid expenses and other current assets consisted of the following (in thousands):
|  | September 30, |  |  | December 31, |
|  | 2024 |  |  | 2023 |
Prepaid insurance |  | $ | 473 |  |  | $ | 428 |
Other receivables |  |  | 96 |  |  |  | 148 |
Prepaid subscriptions and fees |  |  | 148 |  |  |  | 138 |
Prepaid software licenses |  |  | 19 |  |  |  | 64 |
Deposits |  |  | 12 |  |  |  | — |
Deferred equity issuance costs |  |  | 76 |  |  |  | 112 |
Prepaid other |  |  | 6 |  |  |  | 6 |
|  | $ | 830 |  |  | $ | 896 |
Deferred equity issuance costs consist of the legal, accounting and other direct and incremental costs incurred by the Company related to its equity offerings, if not yet finalized as of the balance sheet date, or shelf registration statement. These costs will be netted against additional paid-in capital as a cost of the future equity issuances to which they relate. During the nine months ended September 30, 2024, the Company netted previously deferred equity issuance costs of approximately $37,000 against the additional paid-in capital recognized in conjunction with the warrant inducement transaction that closed on February 1, 2024 (see Note 5, Stockholders' Equity). Other noncurrent assets consisted of the following (in thousands):
|  | September 30, |  |  | December 31, |
|  | 2024 |  |  | 2023 |
Prepaid insurance, less current portion |  | $ | 324 |  |  | $ | 478 |
Other noncurrent assets |  |  | — |  |  |  | 12 |
|  | $ | 324 |  |  | $ | 490 |
Accrued liabilities consisted of the following (in thousands):
|  | September 30, |  |  | December 31, |
|  | 2024 |  |  | 2023 |
Accrued accounts payable |  | $ | 118 |  |  | $ | 146 |
Accrued clinical trial expenses |  |  | 174 |  |  |  | 20 |
Accrued CMC expenses |  |  | 264 |  |  |  | 5 |
Accrued director stipends |  |  | 59 |  |  |  | 106 |
Accrued severance and benefits (Note 9) |  |  | — |  |  |  | 131 |
Accrued joint development expenses (Note 7) |  |  | 669 |  |  |  | 98 |
Current portion of contingent consideration obligation (Note 4) |  |  | — |  |  |  | 143 |
Accrued other |  |  | 225 |  |  |  | 182 |
|  | $ | 1,509 |  |  | $ | 831 |

X
- References No definition available. + Details
Name: | us-gaap_DisclosureTextBlockAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/210/tableOfContent + Details
Name: | us-gaap_SupplementalBalanceSheetDisclosuresTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration